News
Public · Published
Zevra Therapeutics Q3 revenue rises 45% on MIPLYFFA sales
Zevra Therapeutics said third-quarter revenue rose 45% year over year, beating analyst expectations. The company reported net income, reversing a loss from a year earlier, and ended the quarter with cash. Sales of MIPLYFFA, its treatment for Niemann-Pick disease type C, drove revenue growth.
Published:
Updated:
What happened
Zevra Therapeutics said third-quarter revenue rose 45% year over year, beating analyst expectations. The company reported net income, reversing a loss from a year earlier, and ended the quarter with cash. Sales of MIPLYFFA, its treatment for Niemann-Pick disease type C, drove revenue growth.
Confirmed
Global impact / market context
Higher MIPLYFFA sales contributed to revenue growth and a return to quarterly profit, potentially giving Zevra more resources to fund research and commercial activity. However, increased research and development spending on arimoclomol and celiprolol means pipeline investment is also using cash.
Analyst inference
Zevra’s reported revenue exceeded the analyst consensus provided in the article, while the article also reports a buy consensus among covered analysts. Its cash balance and stated ability to support strategic priorities offer context, but future results depend partly on product sales and development progress.
Analyst inference
What to watch
- Watch whether MIPLYFFA sales continue to support revenue growth; the company identified those sales as the driver of the third-quarter increase. Analyst inference
- Zevra is awaiting the EU re-examination outcome for arimoclomol marketing authorization, a decision relevant to whether it can market the drug there. Confirmed
- The company expects to file an sNDA for MIPLYFFA in infants under 24 months in Q1 2027; follow whether that filing occurs as planned. Confirmed
Evidence
- Original source link unavailable